Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02304185 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers
A Phase 1 study, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02304185: Completed Phase 1 study, sponsored by Crucell Holland.
NCT02304185 is a Phase 1 study that has completed, run by Crucell Holland. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02304185, a Phase 1 study, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of 2 different dose levels of trimeric glycoprotein140 (gp140) administered as a 2-dosage regimen, intramuscularly (injection of a substance into a muscle), with and without aluminum phosphate as adjuvant in healthy human immunodeficiency virus (HIV)-uninfected participants.
Interventions
- DRUG Placebo
- BIOLOGICAL gp140, 50 mcg
- BIOLOGICAL gp140, 50 mcg + Adjuvant
- BIOLOGICAL gp140, 250 mcg
- BIOLOGICAL gp140, 250 mcg + Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02304185
The ClinicalTrials.gov registry entry for NCT02304185 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02304185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02304185 about?
NCT02304185 is a clinical study titled "Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers". The purpose of this study is to assess the safety and tolerability of 2 different dose levels of trimeric glycoprotein140 (gp140) administered as a 2-dosage regimen, intramuscularly (injection of a substance into a muscle), with and without aluminum phosphate as adjuvant in healthy human immunodefic...
What is the current status of trial NCT02304185?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02304185?
The interventions under investigation include: Placebo (DRUG), gp140, 50 mcg (BIOLOGICAL), gp140, 50 mcg + Adjuvant (BIOLOGICAL), gp140, 250 mcg (BIOLOGICAL), gp140, 250 mcg + Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02304185?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.